Executive readout · one minute
Call research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
ALLO
$1.60
-1.23%
ALLO
· Allogene Therapeutics, Inc.
$1.60
-0.02 (-1.23%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$563.15M
Shares
345.49M
Volume · Sep 30
8.13M
Avg daily vol (3M)
6.23M
All earnings calls
Earnings call · FY2024 Q2
Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call
Forward guidance
3 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Revenue
$0
-100% YoY
Diluted EPS
-$0.35
Net income
-$66.36M
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Aug 7, 2024.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Decrease in cash, cash equivalents, and investments
2024
|
$200M | — | |
|
GAAP Operating Expenses
2024
|
$300M | GAAP | |
|
Non-cash stock-based compensation expense
2024
|
$60M | GAAP |
SEC filing · Item 2.02
8-K earnings release
Filed Aug 7, 2024 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 7, 2024 · complete as-filed document